Carbohydrate-based adjuvants

Pilar Garcia-Vello*, Immacolata Speciale, Fabrizio Chiodo, Antonio Molinaro, Cristina De Castro

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review


Carbohydrate adjuvants are safe and biocompatible compounds usable as sustained delivery systems and stimulants of ongoing humoral and cellular immune responses, being especially suitable for the development of vaccines against intracellular pathogens where alum is useless. The development of new adjuvants is difficult and expensive, however, in the last two years, seven new carbohydrate-based adjuvants have been patented, also there are twelve ongoing clinical trials of vaccines that contain carbohydrate-based adjuvants, as well as numerous publications on their mechanism of action and safety. More research is necessary to improve the existent adjuvants and develop innovative ones.

Original languageEnglish
Pages (from-to)57-68
Number of pages12
JournalDrug Discovery Today: Technologies
Publication statusPublished - Dec 2020

Cite this